The Effect of Subsequent Pregnancy on Prognosis in Young Breast Cancer Patients (≤35 Years Old) According to Hormone Receptor Status

Figures & data

Video abstract

Figure 1 Schematic diagram for patient selection.

Table 1 Clinicopathological Characteristics of Patients in the Two Groups

Characteristics	Pregnant		Non-Pregnant
	No.	%	No.	%	P
No. of patients	68	20.5	264	79.5
Age, years					<0.01
Median	28(21–34)		33(18–35)
BC family history					0.869
YES	8	11.8	33	12.5
NO	60	88.2	231	87.5
Reproductive history					<0.01
YES	13	19.1	220	83.3
NO	55	80.9	44	16.7
Breastfeeding history					<0.01
YES	12	17.6	199	75.4
NO	56	82.4	65	24.6
TNM size, cm					0.614
Tis	1	1.5	5	1.9
≤2	26	38.2	105	39.8
>2,≤5	37	54.4	147	55.7
>5	4	5.9	7	2.7
Lymph node metastasis					0.386
0	49	72.1	179	67.8
1–3	18	26.5	71	26.9
4–9	1	1.5	14	5.3
Histological grade					0.251
1	5	7.4	7	2.7
2	36	52.9	154	58.3
3	6	8.8	30	11.4
Unknown	21	30.9	73	27.7
Pathological type					0.187
Invasive ductal carcinoma	59	86.8	239	90.5
Invasive lobular carcinoma	0	0	5	1.9
Others	9	13.2	20	7.6
Type of breast Surgery					0.002
Breast-conserving surgery	30	44.1	65	24.6
Mastectomy	38	55.9	199	75.4
Estrogen receptor status					0.821
Positive	43	63.2	163	61.7
Negative	25	36.8	101	38.3
Progesterone receptor status					0.608
Positive	42	61.8	154	58.3
Negative	26	38.2	110	41.7
HER2 status					0.713
Positive	8	11.8	27	10.2
Negative	60	88.2	237	89.8
Neoadjuvant chemotherapy					0.001
YES	14	20.6	19	7.2
NO	54	79.4	245	92.8
Adjuvant chemotherapy regimens					0.593
Anthracycline-based	10	14.7	53	20.1
Anthracycline-and taxane-based	54	79.4	195	73.9
Unknown	4	5.9	16	6.1
Radiotherapy					0.012
YES	38	55.9	99	37.5
NO	29	42.6	147	55.7
Unknown	1	1.5	18	6.8
Adjuvant hormonal therapy					0.071
YES	42	61.8	146	55.3
NO	26	38.2	99	37.5
Unknown	0	0.0	19	7.2
Ovarian function suppression					0.226
YES	12	17.6	28	10.6
NO	44	64.7	175	66.3
Unknown	12	17.6	61	23.1
Targeted therapy					0.592
YES	4	5.9	16	6.1
NO	64	94.1	244	92.4
Unknown	0	0	4	1.5
Molecular subtype					0.998
Luminal type	43	63.2	163	63.0
HER2 over-expression	4	5.9	16	6.2
Triple negative	21	30.9	80	30.9

Table 2 Basic Information of 68 Pregnant Patients in the Follow-Up Visit

Basic Information	n	%
Pregnancy interval
≤5 year	30	44.1
>5 year	38	55.9
Endocrine therapy interval
≤30m	11	16.2
>30m	32	47.1
Recurrence
Yes	3	95.6
No	65	4.4
Death
Yes	0	0
No	68	100.0

Figure 2 Disease-free survival (DFS) of patients in the pregnant group and control group (A) and overall survival (OS) of patients in the pregnant group and control group (B).

Figure 3 Disease-free survival (DFS) of patients in the pregnant group and control group with hormone receptor positive (A) and overall survival (OS) of patients in the pregnant group and control group with hormone receptor positive (B).

Figure 4 Disease-free survival (DFS) of patients in the pregnant group and control group with hormone receptor negative (A) and overall survival (OS) of patients in the pregnant group and control group with hormone receptor negative (B).

Figure 5 Disease-free survival (DFS) of patients with pregnancy intervals ≤ 5 years after surgery and their control group.

Figure 6 Disease-free survival (DFS) of patients with endocrine therapy intervals (≤ 30 months vs >30 months) after surgery in the pregnant group.